Literature DB >> 2379343

Primary Sjögren's syndrome: a subjective description of the disease.

K Bjerrum1, J U Prause.   

Abstract

Forty patients with primary Sjögren's syndrome were interviewed to clarify the onset and course of the disease. In 50% of the cases, the first subjective signs of disease were recorded at age 30 to 50 years. A large variation was, however, observed, and some patients even recalled symptoms as early as in childhood. About one third described the onset as sudden, whereas the rest described an insidious deterioration. Keratoconjunctivitis sicca was the most frequent debut symptom, followed by xerostomia and weariness. Regardless of age, extreme weariness was a major problem. Pain in joints and muscles tended to be more severe in younger patients; ocular and oral problems tended to be more severe the higher the age of debut. Finally, most patients eventually came to have more or less the same complex of symptoms, which could lead to a devastating condition affecting the patients not only physically but also psychically and socially. The large variety of symptoms could easily be overlooked or misinterpreted, and because the patients did not appear to be ill, diagnosis was first established after an average period of nine years. Most patients used artificial tears, and obtained significantly greater benefit from this remedy than from all other drugs. A certain familial disposition towards the disease was found.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379343

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  12 in total

Review 1.  Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

2.  Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren's Syndrome.

Authors:  Hiroshi Yasuda; Hiroshi Niki
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

3.  Leucocytoclastic vasculitis as presenting feature of primary Sjögren's syndrome.

Authors:  H M Markusse; M Schoonbrood; M Oudkerk; S C Henzen-Logmans
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

4.  Sjögren's syndrome: History, clinical and pathological features.

Authors:  A L Parke; W W Buchanan
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

5.  The diagnostic value of salivary fluid levels of beta 2-microglobulin, lysozyme and lactoferrin for primary Sjögren's syndrome.

Authors:  H M Markusse; H G Otten; T M Vroom; T J Smeets; N Fokkens; F C Breedveld
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

6.  Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody.

Authors:  Yang-Seon Ryu; Sung-Hwan Park; Jennifer Lee; Seung-Ki Kwok; Ji-Hyeon Ju; Ho-Youn Kim; Chan-Hong Jeon
Journal:  Rheumatol Int       Date:  2012-11-21       Impact factor: 2.631

7.  Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.

Authors:  Katrine Brække Norheim; Erna Harboe; Lasse G Gøransson; Roald Omdal
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

8.  A five-year prospective study of fatigue in primary Sjögren's syndrome.

Authors:  Karstein Haldorsen; Ingvar Bjelland; Anne Isine Bolstad; Roland Jonsson; Johan Gorgas Brun
Journal:  Arthritis Res Ther       Date:  2011-10-13       Impact factor: 5.156

9.  Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States.

Authors:  Barbara Segal; Simon J Bowman; Philip C Fox; Frederick B Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean
Journal:  Health Qual Life Outcomes       Date:  2009-05-27       Impact factor: 3.186

10.  Diagnostic model of saliva peptide finger print analysis of primary Sjögren's syndrome patients by using weak cation exchange magnetic beads.

Authors:  Pan Wei; Winston Patrick Kuo; Feng Chen; Hong Hua
Journal:  Biosci Rep       Date:  2013-07-16       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.